IL92135A - Method for solubilization and naturation of somatotropin - Google Patents
Method for solubilization and naturation of somatotropinInfo
- Publication number
- IL92135A IL92135A IL9213589A IL9213589A IL92135A IL 92135 A IL92135 A IL 92135A IL 9213589 A IL9213589 A IL 9213589A IL 9213589 A IL9213589 A IL 9213589A IL 92135 A IL92135 A IL 92135A
- Authority
- IL
- Israel
- Prior art keywords
- somatotropin
- range
- pll
- hours
- solution
- Prior art date
Links
- 108010051696 Growth Hormone Proteins 0.000 title claims abstract description 74
- 102000018997 Growth Hormone Human genes 0.000 title claims abstract description 74
- 238000000034 method Methods 0.000 title claims abstract description 42
- 238000005063 solubilization Methods 0.000 title claims abstract description 15
- 230000007928 solubilization Effects 0.000 title claims abstract description 15
- 239000000539 dimer Substances 0.000 claims abstract description 18
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 11
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 6
- 239000000178 monomer Substances 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 241000283690 Bos taurus Species 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims 1
- 239000003398 denaturant Substances 0.000 abstract description 10
- 238000004153 renaturation Methods 0.000 abstract description 4
- 239000012670 alkaline solution Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- 239000000122 growth hormone Substances 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 230000003196 chaotropic effect Effects 0.000 description 7
- 239000008188 pellet Substances 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 108010006025 bovine growth hormone Proteins 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- -1 U.S. Patent No. 4 Chemical compound 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- 239000012510 hollow fiber Substances 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108091006522 Anion exchangers Proteins 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 108700031632 somatrem Proteins 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/285,477 US5064943A (en) | 1988-12-16 | 1988-12-16 | Method for solubilization and naturation of somatotropin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL92135A0 IL92135A0 (en) | 1990-07-12 |
| IL92135A true IL92135A (en) | 1995-05-26 |
Family
ID=23094405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9213589A IL92135A (en) | 1988-12-16 | 1989-10-27 | Method for solubilization and naturation of somatotropin |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5064943A (da) |
| EP (1) | EP0373325B1 (da) |
| JP (1) | JPH02222697A (da) |
| KR (1) | KR0148681B1 (da) |
| AT (1) | ATE136309T1 (da) |
| AU (1) | AU628443B2 (da) |
| CA (1) | CA2005478C (da) |
| DE (1) | DE68926153T2 (da) |
| DK (1) | DK174662B1 (da) |
| ES (1) | ES2087065T3 (da) |
| FI (1) | FI102179B (da) |
| GR (1) | GR3019691T3 (da) |
| HU (1) | HU213572B (da) |
| IE (1) | IE74848B1 (da) |
| IL (1) | IL92135A (da) |
| NZ (1) | NZ231681A (da) |
| PT (1) | PT92305B (da) |
| ZA (1) | ZA899626B (da) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5340926A (en) * | 1983-03-25 | 1994-08-23 | Celltech, Limited | Process for the recovery of recombinantly produced protein from insoluble aggregate |
| US5332805A (en) * | 1984-02-03 | 1994-07-26 | Celltech Limited | Process for the recovery of recombinantly produced chymosin from insoluble aggregate |
| US5317324A (en) * | 1991-06-20 | 1994-05-31 | Sumitomo Metal Mining Co., Ltd. | Printed antenna |
| US5151501A (en) * | 1991-12-20 | 1992-09-29 | American Cyanamid Company | Method for solubilization and naturation of somatotropins utilizing sulfolane |
| AU4665193A (en) * | 1992-07-02 | 1994-01-31 | Pitman-Moore, Inc. | A process for recovering a recombinant protein, in biologically active form, from a solution containing inactive protein |
| ZA94169B (en) * | 1993-01-26 | 1994-09-07 | Lilly Co Eli | Non-denaturing potency assay for bovine somatotropin |
| US5567620A (en) * | 1993-01-26 | 1996-10-22 | Eli Lilly And Company | Non-denaturing potency assay for somatotropin |
| EP1095056B1 (en) | 1998-07-09 | 2006-12-27 | BaroFold, Inc. | High pressure refolding of protein aggregates and inclusion bodies |
| EP1149160B1 (en) * | 1999-01-25 | 2006-04-19 | Novozymes A/S | Recovery of a protein at high ph |
| CA2434045A1 (en) * | 2000-10-31 | 2002-08-15 | The Regents Of The University Of Colorado, A Body Corporate | Improved protein disaggregation and refolding using high pressure |
| CA2443365C (en) * | 2002-11-19 | 2010-01-12 | F. Hoffmann-La Roche Ag | Methods for the recombinant production of antifusogenic peptides |
| AR062069A1 (es) * | 2006-07-14 | 2008-10-15 | Genentech Inc | Replegado de proteinas recombinantes |
| CA2663416A1 (en) * | 2006-09-15 | 2008-03-20 | Barofold, Inc. | High pressure treatment of proteins for reduced immunogenicity |
| BR102013026129A2 (pt) * | 2013-10-10 | 2016-05-24 | Ouro Fino Participações E Empreendimentos S A | processo para a produção de somatotropina bovina recombinate ativa e produto obtido |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE55163B1 (en) * | 1982-06-07 | 1990-06-20 | Celltech Ltd | A process for the preparation of chymosin |
| US4511503A (en) * | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
| EP0122080B1 (en) * | 1983-03-25 | 1989-09-13 | Celltech Limited | A process for the production of a protein |
| CA1267615A (en) * | 1984-08-27 | 1990-04-10 | Dan Hadary | Method for recovering purified growth hormones from genetically engineered microorganisms |
| ES8800957A1 (es) * | 1985-02-22 | 1987-12-01 | Monsanto Co | Un metodo para la solubilizacion y renaturalizacion de proteina somatotropina |
| US4652630A (en) * | 1985-02-22 | 1987-03-24 | Monsanto Company | Method of somatotropin naturation |
| US4677196A (en) * | 1985-09-06 | 1987-06-30 | International Minerals & Chemical Corp. | Purification and activation of proteins from insoluble inclusion bodies |
| AU3439089A (en) * | 1988-08-05 | 1990-03-05 | Ralph Akyuz | Skin protection lotion |
| JP2531272B2 (ja) * | 1988-08-11 | 1996-09-04 | 日本電気株式会社 | フレ―ム同期制御方式 |
-
1988
- 1988-12-16 US US07/285,477 patent/US5064943A/en not_active Expired - Lifetime
-
1989
- 1989-10-19 ES ES89119409T patent/ES2087065T3/es not_active Expired - Lifetime
- 1989-10-19 EP EP89119409A patent/EP0373325B1/en not_active Expired - Lifetime
- 1989-10-19 DE DE68926153T patent/DE68926153T2/de not_active Expired - Fee Related
- 1989-10-19 AT AT89119409T patent/ATE136309T1/de not_active IP Right Cessation
- 1989-10-27 IL IL9213589A patent/IL92135A/en not_active IP Right Cessation
- 1989-11-06 IE IE356189A patent/IE74848B1/en not_active IP Right Cessation
- 1989-11-14 PT PT92305A patent/PT92305B/pt not_active IP Right Cessation
- 1989-12-08 NZ NZ231681A patent/NZ231681A/xx unknown
- 1989-12-14 JP JP1322768A patent/JPH02222697A/ja active Pending
- 1989-12-14 CA CA002005478A patent/CA2005478C/en not_active Expired - Fee Related
- 1989-12-14 AU AU46750/89A patent/AU628443B2/en not_active Expired
- 1989-12-15 FI FI896021A patent/FI102179B/fi not_active IP Right Cessation
- 1989-12-15 KR KR1019890018683A patent/KR0148681B1/ko not_active Expired - Fee Related
- 1989-12-15 DK DK198906390A patent/DK174662B1/da not_active IP Right Cessation
- 1989-12-15 ZA ZA899626A patent/ZA899626B/xx unknown
- 1989-12-15 HU HU896639A patent/HU213572B/hu not_active IP Right Cessation
-
1996
- 1996-04-22 GR GR950403213T patent/GR3019691T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2005478C (en) | 2000-01-04 |
| FI102179B1 (fi) | 1998-10-30 |
| FI896021A0 (fi) | 1989-12-15 |
| IE74848B1 (en) | 1997-08-13 |
| HU213572B (en) | 1997-08-28 |
| JPH02222697A (ja) | 1990-09-05 |
| DK639089D0 (da) | 1989-12-15 |
| AU628443B2 (en) | 1992-09-17 |
| EP0373325A3 (en) | 1991-06-12 |
| CA2005478A1 (en) | 1990-06-16 |
| EP0373325A2 (en) | 1990-06-20 |
| HU896639D0 (en) | 1990-02-28 |
| DE68926153T2 (de) | 1996-10-24 |
| DK639089A (da) | 1990-06-17 |
| ZA899626B (en) | 1990-09-26 |
| EP0373325B1 (en) | 1996-04-03 |
| ES2087065T3 (es) | 1996-07-16 |
| DK174662B1 (da) | 2003-08-18 |
| PT92305B (pt) | 1995-07-18 |
| AU4675089A (en) | 1990-06-21 |
| PT92305A (pt) | 1990-06-29 |
| FI102179B (fi) | 1998-10-30 |
| US5064943A (en) | 1991-11-12 |
| KR0148681B1 (ko) | 1998-08-01 |
| GR3019691T3 (en) | 1996-07-31 |
| IE893561L (en) | 1990-06-16 |
| ATE136309T1 (de) | 1996-04-15 |
| KR900009971A (ko) | 1990-07-06 |
| HUT52563A (en) | 1990-07-28 |
| DE68926153D1 (de) | 1996-05-09 |
| NZ231681A (en) | 1993-09-27 |
| IL92135A0 (en) | 1990-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5064943A (en) | Method for solubilization and naturation of somatotropin | |
| EP0215625B1 (en) | Protein recovery | |
| DE69636739T2 (de) | Verfahren zur rückfaltung von menschlichem activin a | |
| IE860466L (en) | Somatotropin solubilisation and naturation | |
| AU615485B2 (en) | Method for promoting intramolecular disulfide bond formation in recombinant proteins contained in denaturant solution | |
| US4801691A (en) | Method for removing sodium dodecyl sulfate from sodium dodecyl sulfate solubilized protein solutions | |
| EP0547102A1 (en) | Solubilization of proteins in active forms | |
| EP0432419B1 (en) | Method for solubilization and naturation of somatotropins utilizing low urea concentration | |
| AU739394B2 (en) | Process for the preparation of active somatotropin from inclusion bodies | |
| EP0529086B1 (en) | Process for purifying human bcdf | |
| US6034224A (en) | Method for solubilization and naturation of somatotropins | |
| US5773588A (en) | Method for purifying somatotropin monomers | |
| US5151501A (en) | Method for solubilization and naturation of somatotropins utilizing sulfolane |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |